Evidence map›Paper›PMID 38012959›Full record

Trial reportThe Journal of infectious diseases2024

High Risk of New HPV Infection Acquisition Among Unvaccinated Young Men.

Anna R Giuliano, Joel M Palefsky, Stephen E Goldstone, Brady Dubin, Alfred Saah, Alain Luxembourg, Christine Velicer, Joseph E Tota

Erratum issued Registry-linked trialOpen access · hybridAbstract readMulticenter StudyRandomized Controlled TrialClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT00090285 (An Investigational Vaccine in Reducing the Incidence of Anogenital Warts in Young Men), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00090285 phase3completednot on this map

An Investigational Vaccine in Reducing the Incidence of Anogenital Warts in Young Men

TypeinterventionalSponsorMerck Sharp & Dohme LLCRan2004 to 2017Enrolled4,065ConditionsCondylomata AcuminataArms(Gardasil™) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine, Comparator: placebo (unspecified)
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Immune Responses to Human Papillomavirus After Infection and Vaccination.Current topics in microbiology and immunology · 2026
    Review
  3. The effects of human papillomavirus vaccination in Japan.Human vaccines & immunotherapeutics · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Anna R GiulianoCenter for Immunization and Infection Research in Cancer, Moffitt Cancer Center, Tampa, Florida, USA.
Joel M PalefskyUniversity of California SanFrancisco, San Francisco, California, USA.
Stephen E GoldstoneIcahn School of Medicine at Mount Sinai, NewYork, New York, USA.
Brady DubinMerck & Co, Inc, Rahway, New Jersey, USA.
Alfred SaahMerck & Co, Inc, Rahway, New Jersey, USA.
Alain LuxembourgMerck & Co, Inc, Rahway, New Jersey, USA.
Christine VelicerMerck & Co, Inc, Rahway, New Jersey, USA.
Joseph E TotaMerck & Co, Inc, Rahway, New Jersey, USA.
Merck & Co., Inc., Rahway, NJ, USA (United States) · USIcahn School of Medicine at Mount Sinai · USMoffitt Cancer Center · USUniversity of California, San Francisco · US

Funding

Merck & Co, IncMerck Sharp & Dohme, LLC
6 · The paper itself

Abstract

backgroundInternational data on anogenital HPV infection incidence among men are limited.

methodsIncidence of incident-persistent (IP) anogenital HPV infections was evaluated among 295 men who have sex with men (MSM) and 1576 heterosexual men (HM) aged 16-27 years in the placebo arm of a global, multicenter 4-valent (4v) HPV vaccine trial. We estimated IP incidence (penile/scrotal, perineal/perianal, anal) for 4vHPV and 9-valent (9v) HPV vaccine types and cumulative IP incidence over 36 months.

resultsIP infection incidence per 100 person-years (95% CI) among HM for 4vHPV and 9vHPV types was 4.1 (3.5-4.9) and 6.8 (5.9-7.6) at penile/scrotal, and 1.2 (.8-1.6) and 1.9 (1.5-2.4) at perineal/perianal sites, respectively; and among MSM, IP infection incidence was 2.3 (1.3-3.8) and 3.2 (2.0-4.9) at penile/scrotal, 6.8 (4.9-9.2) and 9.0 (6.9-11.6) at perineal/perianal, and 12.0 (9.4-15.1) and 16.8 (13.7-20.2) at anal sites, respectively. Cumulative IP incidence over 36 months (excluding anal canal; any 9vHPV type) was higher among MSM versus HM (24.1% vs 18.4%).

conclusionsA substantial proportion of unvaccinated men of catch-up vaccination age developed IP 9vHPV-related infections. Gender-neutral vaccination could decrease male HPV infection, contribute to herd protection, and reduce disease burden. Clinical Trials Registration. NCT00090285.

Indexed as

Papillomavirus InfectionsPapillomavirus VaccinesSexual and Gender MinoritiesAdolescentAdultHomosexuality, MaleHumansMalePapillomaviridaeUnvaccinated PersonsYoung AdultPapillomavirus VaccinesHPV infectionHPV vaccineshuman papillomavirus

Identifiers

PMID38012959
PMCPMC10938197
OpenAlexW4389096551

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.